SNGX Stock Overview A late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States. More details
Rewards Risk Analysis + 1 more risk
See All Risk Checks Capture your thoughts, links and company narrative
Soligenix, Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for Soligenix Historical stock prices Current Share Price US$3.20 52 Week High US$14.92 52 Week Low US$1.83 Beta 1.77 1 Month Change -7.65% 3 Month Change -17.95% 1 Year Change -76.13% 3 Year Change -97.94% 5 Year Change -99.36% Change since IPO -99.99%
Recent News & Updates
Soligenix, Inc. Initiates Confirmatory Phase 3 Clinical Trial of HyBryte for the Treatment of Cutaneous T-Cell Lymphoma Dec 16
Soligenix, Inc. Announces Formation of European Medical Advisory Board for Cutaneous T-Cell Lymphoma Nov 20
Soligenix Initiates A Phase 2 Clinical Trial of SGX945 (Dusquetide) for the Treatment of Behcet's Disease Nov 14
Third quarter 2024 earnings released: US$0.78 loss per share (vs US$2.56 loss in 3Q 2023) Nov 10
Soligenix, Inc. Announces HyBryte Expanded Treatment Results to Be Presented at the European Organisation for Research and Treatment of Cancer Conference Oct 07
Consensus revenue estimates decrease by 28%, EPS upgraded Aug 16 See more updates
Soligenix, Inc. Initiates Confirmatory Phase 3 Clinical Trial of HyBryte for the Treatment of Cutaneous T-Cell Lymphoma Dec 16
Soligenix, Inc. Announces Formation of European Medical Advisory Board for Cutaneous T-Cell Lymphoma Nov 20
Soligenix Initiates A Phase 2 Clinical Trial of SGX945 (Dusquetide) for the Treatment of Behcet's Disease Nov 14
Third quarter 2024 earnings released: US$0.78 loss per share (vs US$2.56 loss in 3Q 2023) Nov 10
Soligenix, Inc. Announces HyBryte Expanded Treatment Results to Be Presented at the European Organisation for Research and Treatment of Cancer Conference Oct 07
Consensus revenue estimates decrease by 28%, EPS upgraded Aug 16
Price target decreased by 13% to US$35.00 Aug 12
Second quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind Aug 11
Soligenix, Inc. Announces Significant Progress in the Treatment of Cutaneous T-Cell Lymphoma with its Investigational Drug, HyBryte™ Aug 02
Soligenix, Inc. Announces an Interim Update on the Open-Label, Investigator-Initiated Study Evaluating Extended HyBryte Treatment for Up to 12 Months in Patients with Early-Stage Cutaneous T-Cell Lymphoma Jul 10
Soligenix, Inc. Announces Positive Clinical Results from A Comparative Study Evaluating Hybryte™? Against Valchlor®? in the Treatment of Cutaneous T-Cell Lymphoma Jun 25
Soligenix, Inc. Announces Positive Clinical Results from HyBryte Compatibility Study in the Treatment of Cutaneous T-Cell Lymphoma May 18
Consensus revenue estimates decrease by 13%, EPS upgraded May 17
Price target decreased by 29% to US$2.50 May 15
First quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind May 13
Soligenix, Inc., Annual General Meeting, May 23, 2024 May 01
Soligenix Extends Patent Protection for Its Filovirus Vaccine Platform to the United Kingdom and South Africa Apr 27
Consensus EPS estimates upgraded to US$0.63 loss Apr 25
Price target increased by 7.7% to US$3.50 Apr 12
Soligenix Announces Agreement on the Design of Second Confirmatory Placebo-Controlled Trial for Hybryte™ with the European Medicines Agency Apr 04
Consensus revenue estimates decrease by 11%, EPS upgraded Mar 22
Full year 2023 earnings: EPS and revenues exceed analyst expectations Mar 17
No longer forecast to breakeven Mar 17
Soligenix, Inc. Announces Formation of Behçet's Disease Medical Advisory Board Feb 08
FDA Grants Soligenix "Fast Track" Designation for Dusquetide in the Treatment of Oral Lesions of Behçet's Disease Jan 09
Soligenix Announces Top-Line Results of the Phase 2A Study of Sgx302 (Synthetic Hypericin) in Patients with Mild-To-Moderate Psoriasis Jan 05
Soligenix Announces Publication Demonstrating Complete Protection Against Filovirus Disease in Nonhuman Primate Models of Ebola and Marburg Viruses Jan 02
Soligenix Receives Written Notice from Nasdaq Regarding Non-Compliance with the Minimum Bid Price Rule and Not Eligible for Second 180 Day Period Dec 24
New major risk - Share price stability Dec 01
Soligenix, Inc. Receives FDA IND Clearance for Phase 2 Clinical Trial of Dusquetide in Treatment of Aphthous Ulcers in Behçet's Disease Nov 30
Consensus EPS estimates upgraded to US$0.83 loss, revenue downgraded Nov 20
Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind Nov 16
Price target decreased by 35% to US$3.25 Nov 14
Insufficient new directors Nov 14
Soligenix, Inc. Announces HyBryte(TM) Expanded Treatment Trial in Cutaneous T-Cell Lymphoma Opens Enrollment Aug 11
Soligenix, Inc., Annual General Meeting, Sep 21, 2023 Aug 08
Soligenix Announces Expansion of SGX302 (Synthetic Hypericin) Phase 2a Study in Mild-to-Moderate Psoriasis Jul 12
Timothy R. Coté Resigned as A Member of the Board of Directors of Soligenix, Inc Jul 10
Consensus revenue estimates increase by 13% May 31
Soligenix Regains Compliance with the Shareholders’ Equity Requirement and in Compliance with All Other Applicable Requirements for Listing on Nasdaq May 29
First quarter 2023 earnings: EPS and revenues exceed analyst expectations May 18
Soligenix, Inc. Announces Scheduling of Type A Meeting with the U.S. FDA to Review Proposed Study Design for a Second Phase 3 Study Evaluating HyBryte(TM) in the Treatment of Cutaneous T-Cell Lymphoma May 12
Soligenix Announces Positive Clinical Results from Compatibility Study of HyBryte in the Treatment of Cutaneous T-Cell Lymphoma May 05
Soligenix, Inc. Announces Appointment of Timothy R. Coté, M.D. to Its Board of Directors May 04
No longer forecast to breakeven Apr 08
Consensus revenue estimates decrease by 76%, EPS upgraded Apr 06
No longer forecast to breakeven Apr 04
Soligenix, Inc. Receives Refusal to File Letter from U.S. FDA for Hybryte™ New Drug Application in the Treatment of Cutaneous T-Cell Lymphoma Feb 15
Soligenix Announces Publication Demonstrating Positive Correlates of Protection with Rivax® in Non-Human Primate Survival After Ricin Challenge Dec 21
Soligenix, Inc. Initiates Phase 2 Clinical Trial of SGX302 (Synthetic Hypericin) for the Treatment of Mild-To-Moderate Psoriasis Dec 20
Soligenix Announces Submission of New Drug Application to the FDA for Hybryte™ in the Treatment of Cutaneous T-Cell Lymphoma Dec 16
Soligenix Receives Non Compliance Notice from Nasdaq Nov 21
Insufficient new directors Nov 17
Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind Nov 13
Soligenix: A Biotech Bargain Ready To File For Approval In Cutaneous T-Cell Lymphoma Oct 05
U.S. FDA awards $2.6M grant for expanded study of Soligenix's HyBryte for skin cancer Sep 12
Soligenix, Inc. Announces U.S. Food and Drug Administration Awards $2.6 Million Orphan Products Development Grant for Expanded Study of HyBryte in the Treatment of Cutaneous T-Cell Lymphoma Sep 07
Soligenix announces $2.6M FDA grant to further study blood cancer candidate Sep 06
Is Soligenix (NASDAQ:SNGX) Using Debt Sensibly? Sep 06
Second quarter 2022 earnings: EPS and revenues exceed analyst expectations Aug 13
Soligenix GAAP EPS of -$0.06 beats by $0.03, revenue of $0.4M beats by $0.2M Aug 12
Soligenix, Inc., Annual General Meeting, Sep 22, 2022 Aug 06
Soligenix, Inc. Receives Agreement from FDA on Initial Pediatric Study Plan for HyBryte for the Treatment of Cutaneous T-Cell Lymphoma Jul 28
Soligenix, SERB Pharma team up to develop therapy for ricin poisoning Jul 25
Soligenix, Inc. Announces HyBryte™ Phase 3 FLASH Study for the Treatment of Cutaneous T-Cell Lymphoma Published in JAMA Dermatology Jul 21
Soligenix, Inc. Receives FDA IND Clearance for Phase 2 Clinical Trial of Synthetic Hypericin in Treatment of Psoriasis Jun 29
Soligenix Announces Successful Protection Using A Bivalent Thermostabilized Filovirus Vaccine Jun 24
Soligenix Receives US Patent Allowance for Its Thermostabilized Vaccine Platform May 24
Price target decreased to US$3.88 May 20
First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind May 14
Insufficient new directors Apr 27
Is Soligenix (NASDAQ:SNGX) Using Debt Sensibly? Apr 22
Consensus forecasts updated Apr 05
No longer forecast to breakeven Apr 02
Full year 2021 earnings: EPS and revenues exceed analyst expectations Mar 30
Soligenix, Inc. Demonstrates Positive Anti-Tumor Efficacy in Multiple Nonclinical Animal Studies Jan 05
Is Soligenix (NASDAQ:SNGX) Using Too Much Debt? Jan 03
Forecast to breakeven in 2024 Jan 01
Third quarter 2021 earnings released: US$0.088 loss per share (vs US$0.061 loss in 3Q 2020) Nov 15
Soligenix Announces Accelerated Publication Demonstrating Efficacy and Broad Neutralizing Activity of Its Covid-19 Vaccine in Non-Human Primates Oct 01
Shareholders May Find It Hard To Justify Increasing Soligenix, Inc.'s (NASDAQ:SNGX) CEO Compensation For Now Sep 17
Health Check: How Prudently Does Soligenix (NASDAQ:SNGX) Use Debt? Aug 30
Soligenix Shares Preclinical Data Demonstrating That Its Thermostable Vaccine Platform May Be an Important Contributor to Addressing the Next Potential Pandemic and Future Health Emergencies Aug 25
Soligenix, Inc. Announces Publication Demonstrating Successful Formulation and Heat Stabilization of Filovirus Vaccine Platform for Ebola and Marburg Virus Diseases Aug 24
Consensus forecasts updated Aug 20
Price target decreased to US$3.75 Aug 18
Second quarter 2021 earnings released: US$0.047 loss per share (vs US$0.10 loss in 2Q 2020) Aug 18
Soligenix, Inc. announced delayed 10-Q filing May 19
First quarter 2021 earnings released: US$0.064 loss per share (vs US$0.32 loss in 1Q 2020) May 19
Soligenix, Inc. Plans to Submit Nda May 08
Is Soligenix (NASDAQ:SNGX) Weighed On By Its Debt Load? May 08
Consensus revenue estimates fall to US$1.07m Apr 06
Full year 2020 earnings released: US$0.64 loss per share (vs US$0.48 loss in FY 2019) Apr 01
What Type Of Returns Would Soligenix's(NASDAQ:SNGX) Shareholders Have Earned If They Purchased Their SharesFive Years Ago? Mar 16
Soligenix, Inc. Announces Positive Progress in the Pre-clinical Development of its COVID-19 Vaccine Mar 06
Soligenix Receives Hong Kong Patent for Therapeutic Use of Synthetic Hypericin to Treat Cutaneous T-Cell Lymphoma Feb 02 Shareholder Returns SNGX US Biotechs US Market 7D 2.2% -2.4% -2.1% 1Y -76.1% -8.7% 21.3%
See full shareholder returns
Return vs Industry: SNGX underperformed the US Biotechs industry which returned -6.4% over the past year.
Return vs Market: SNGX underperformed the US Market which returned 23.2% over the past year.
Price Volatility Is SNGX's price volatile compared to industry and market? SNGX volatility SNGX Average Weekly Movement 9.0% Biotechs Industry Average Movement 11.2% Market Average Movement 6.4% 10% most volatile stocks in US Market 18.8% 10% least volatile stocks in US Market 3.2%
Stable Share Price: SNGX has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: SNGX's weekly volatility has decreased from 41% to 9% over the past year.
About the Company Soligenix, Inc., a late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States. The company operates through two segments, Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops SGX301 (HyBryte), a novel photodynamic therapy, which has completed Phase III clinical trial for the treatment of cutaneous T-cell lymphoma; SGX942, an innate defense regulator technology that is in Phase III clinical trial for the treatment of inflammatory diseases, including oral mucositis in head and neck cancer; SGX302, an IDR technology which is in Phase IIa study to treat mil-to-moderate Psoriasis; and SGX945 and IDR technology that is in Phase IIa protocol for the treatment of Aphthous Ulcers in Behçet’s Disease.
Show more Soligenix, Inc. Fundamentals Summary How do Soligenix's earnings and revenue compare to its market cap? SNGX fundamental statistics Market cap US$8.21m Earnings (TTM ) -US$7.10m Revenue (TTM ) US$364.18k
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) SNGX income statement (TTM ) Revenue US$364.18k Cost of Revenue US$340.92k Gross Profit US$23.27k Other Expenses US$7.12m Earnings -US$7.10m
Last Reported Earnings
Sep 30, 2024
Earnings per share (EPS) -2.83 Gross Margin 6.39% Net Profit Margin -1,949.32% Debt/Equity Ratio 34.7%
How did SNGX perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2025/01/10 17:41 End of Day Share Price 2025/01/10 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Soligenix, Inc. is covered by 6 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution James Molloy Alliance Global Partners Jonathan Aschoff Brean Capital Andrew D'Silva B. Riley Securities, Inc.
Show 3 more analysts 
